Literature DB >> 8912544

High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer.

B G Taal1, B M Aleman, C C Koning, H Boot.   

Abstract

To induce fast relief of dysphagia in patients with oesophageal cancer high dose rate (HDR) brachytherapy was applied before external radiotherapy in a prospective study. Seventy-four patients with inoperable oesophageal cancer (36 squamous cell, 38 adenocarcinoma) were treated with a combination of 10 Gy HDR brachytherapy, followed by 40 Gy in 4 weeks external beam radiotherapy (EBRT), starting 2 weeks later. Tumour response, as measured by endoscopy and/or barium swallow, revealed complete remission in 21 and partial response in 38 patients (overall response rate 80%). Improvement of dysphagia was induced by brachytherapy within a few days in 39%, and achieved at the end of treatment in 70% of patients. Further weight loss was prevented in 39 of the 59 patients who presented with weight loss. Pain at presentation improved in 12 out of 25 patients. Median survival was 9 months. No differences in either response rate or survival were found in squamous cell or adenocarcinoma. Side-effects were either acute with minimal discomfort in 32 (42%) or late with painful ulceration in five patients (7%), occurring after a median of 4 months. A fistula developed in six patients, all with concurrent tumour. In conclusion, brachytherapy before EBRT was a safe and effective procedure to induce rapid relief of dysphagia, especially when combined with EBRT.

Entities:  

Mesh:

Year:  1996        PMID: 8912544      PMCID: PMC2074787          DOI: 10.1038/bjc.1996.564

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Palliation of malignant dysphagia: surgery, radiotherapy, laser, intubation alone or in combination?

Authors:  S G Bown
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

Review 2.  Radiotherapy alone in esophageal carcinoma: current management and future directions of adjuvant, curative and palliative approaches.

Authors:  S R Smalley; L L Gunderson; E K Reddy; S Williamson
Journal:  Semin Oncol       Date:  1994-08       Impact factor: 4.929

3.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.

Authors:  A Herskovic; K Martz; M al-Sarraf; L Leichman; J Brindle; V Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami
Journal:  N Engl J Med       Date:  1992-06-11       Impact factor: 91.245

4.  External beam and intraluminal radiotherapy in the treatment of carcinoma of the esophagus.

Authors:  E C Hyden; B Langholz; T Tilden; K Lam; G Luxton; M Astrahan; J Jepson; Z Petrovich
Journal:  J Thorac Cardiovasc Surg       Date:  1988-08       Impact factor: 5.209

5.  Radiation therapy of esophageal cancer: role of high dose rate brachytherapy.

Authors:  R K Sur; D P Singh; S C Sharma; M T Singh; R Kochhar; P S Negi; T Sethi; F Patel; S Ayyagari; S P Bhatia
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

6.  Radiation Therapy for Esophageal Cancer: Improving the Therapeutic Ratio.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1994-07       Impact factor: 5.934

7.  Non-cancerous ulcer in the esophagus after radiotherapy for esophageal carcinoma--a report of 27 patients.

Authors:  Z Y Yang; Y H Hu; X Z Gu
Journal:  Radiother Oncol       Date:  1990-10       Impact factor: 6.280

8.  Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.

Authors:  L R Coia; P F Engstrom; A R Paul; P M Stafford; G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-01       Impact factor: 7.038

9.  Intraluminal brachytherapy using the high dose rate microSelectron in the palliation of carcinoma of the oesophagus.

Authors:  A E Brewster; S E Davidson; W P Makin; R Stout; P A Burt
Journal:  Clin Oncol (R Coll Radiol)       Date:  1995       Impact factor: 4.126

10.  Carcinoma of the esophagus: pretreatment assessment, correlation of radiation treatment parameters with survival, and identification and management of radiation treatment failure.

Authors:  J D Beatty; G DeBoer; W D Rider
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

View more
  6 in total

1.  Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus.

Authors:  Á Rovirosa; J Anchuelo; V Crispin; C Gutiérrez; A Herreros; I Herruzo; J C Menéndez; P Pino; A Polo; S Rodríguez
Journal:  Clin Transl Oncol       Date:  2015-04-17       Impact factor: 3.405

2.  Argon plasma coagulation compared with stent placement in the palliative treatment of inoperable oesophageal cancer.

Authors:  Dimitrios E Sigounas; Christoforos Krystallis; Graeme Couper; Simon Paterson-Brown; Athina Tatsioni; John N Plevris
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

3.  Computed organ doses to an Indian reference adult during brachytherapy treatment of esophagus, breast, and neck cancers.

Authors:  Biju Keshavkumar
Journal:  J Med Phys       Date:  2012-07

4.  High-dose-rate intraluminal brachytherapy prior to external radiochemotherapy in locally advanced esophageal cancer: preliminary results.

Authors:  Afsaneh Maddah Safaei; Reza Ghalehtaki; Nezhat Khanjani; Borna Farazmand; Mohammad Babaei; Ebrahim Esmati
Journal:  J Contemp Brachytherapy       Date:  2017-01-13

5.  Why is a very easy, useful, old technique underused? An overview of esophageal brachytherapy - interventional radiotherapy.

Authors:  Albert Biete; György Kovács; Ángeles Rovirosa; Luca Tagliaferri; Adam Chicheł; Valentina Lancellotta; Yaowen Zhang; Gabriela Antelo; Peter Hoskin; Elzbieta Van Der Steen-Banasik
Journal:  J Contemp Brachytherapy       Date:  2022-06-30

6.  Cost study of metal stent placement vs single-dose brachytherapy in the palliative treatment of oesophageal cancer.

Authors:  S Polinder; M Y V Homs; P D Siersema; E W Steyerberg
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.